Leczenie eksperymentalne COVID-19

Leczenie eksperymentalne COVID-19 – strategie terapeutyczne mające na celu znalezienie leków skutecznych w zwalczaniu choroby COVID-19.

W związku z pandemią COVID-19 w 2020 r. w wielu ośrodkach na świecie rozpoczęto intensywne poszukiwania leków mających zastosowanie w leczeniu COVID-19[1]. Do analizowanych terapii zaliczają się procedury z wykorzystaniem leków przeciwwirusowych, przeciwciał monoklonalnych, peptydów, oligonukleotydów, interferonów, a także szczepionki. W celu jak najszybszego wprowadzenia leków na COVID-19 badane są możliwości wykorzystania istniejących leków mających dotychczas inne zastosowania. Można do nich zaliczyć m.in. leki przeciw wirusom HIV, HBV, HCV, grypy oraz inne, oparte na doświadczeniu w leczeniu infekcji wywołanych przez koronawirusy, takich jak SARS i MERS[1][2][3].

Amantadyna

Badania kliniczne nad skutecznością amantadyny w Polsce rozpoczęto w kwietniu 2021 w którym uczestniczą między innymi Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie[4] i Śląski Uniwersytet Medyczny w Katowicach[5]. Przeprowadzone badania nie wykazały skuteczności amantadyny w leczeniu COVID-19[6]

Lista leków eksperymentalnych stosowanych w leczeniu COVID-19
LekLokalizacja badania
RemdesiwirHubei, Chiny[7]

Pekin, Chiny[8]

międzynarodowe[9]

inne[10][11]

Hiszpania[12][13]

TocilizumabAnhui, Chiny[14]

Shaanxi, Chiny[15]

Wielka Brytania, inne[16][17][18]

Lopinawir + rytonawirWuhan, Chiny[19][7][20]

Guangdong, Chiny[8][21]

Hongkong[10]

Uniwersytet Zhejiang, Chiny[11]

Jiangxi, Chiny[22][23]

Chongqing, Chiny[24][25]

Hubei, Chiny[26][27]

różne miasta[28][29]

Syczuan, Chiny[30]

Zhejiang, Chiny[31]

Zhuhai, Chiny[32]

LopinawirZhejiang, Chiny[33]
ASC09 + rytonawirUniwersytet Zhejiang, Chiny[11]; Chongqing, Chiny[25]
Danoprewir + rytonawirJiangxi, Chiny[22]
FawipirawirZhejiang, Chiny[31]

Guangdong, Chiny[34][35]

Pekin, Chiny[36]

Wuhan, Chiny[37]

Fawipirawir + bromoheksynaZhejiang, Chiny[38]
RybawirynaHong kong[10]Chongqing, Chiny[24]
UmifenowirChongqing, Chiny[25]

różne miasta, Chiny[28]

Tongji, Chiny[39]

Szanghaj, Chiny[40]

Zhejiang, Chiny[33]

Szanghaj, Chiny[41][42]

Hubei, Chiny[43][44]

Ruijin, Chiny[42]

Komórki macierzysteHubei, Chiny[45][46][47][48][49][50][51][52]

Pekin, Chiny[53]

Zhejiang, Chiny[54]

Chiny[55][56][57]

Guangdong, Chiny[58][59][60][61]

Pekin, Hubei, Szanghaj, Chiny[62]

Pekin, Chiny[63]

Jiangxi, Chiny[64]

nieznana[65]

Darunawir + kobicystatSzanghaj, Chiny[66]

Hubei, Chiny[67]

AzwudynaHenan, Chiny[68][69][70]
TriazawirynaHeilongjiang, Chiny[71]
EmtrycytabinaSyczuan, Chiny[30]
Marboksyl baloksawiruZhejiang, Chiny[31]

Guangdong, Chiny[34]

Alafenamid tenofowiruSyczuan, Chiny[30]
NowaferonJiangxi, Chiny[22]Zhejiang, Chiny[33]
Peginterferon alfa-2aJiangxi, Chiny[22]
Interferon beta-1bHong kong[10]
Interferon alfa-1bChongqing, Chiny[24]Tongji, Chiny[72]

Hubei, Chiny[73]

InterferonSyczuan, Chiny[74]

Hunan, Chiny[75]

Szanghaj, Chiny[76]

Tradycyjne leki chińskieJiangxi, Chiny[22]
Chlorochinaróżne miasta, Chiny[28]

Szanghaj, Chiny[77] Guangdong, Chiny[78][21][79]

Hubei, Chiny[80]

Zhunghai, Chiny[32]

Hubei, Chiny[81][82][83]

Chongqing, Chiny[84][85]różne miasta, Chiny[86][87][88]

Jilin, Chiny[89]

Heilongjiang, Chiny[90]

Hydroksychlorochinaróżne miasta, Chiny[86][87][88]

Hubei, Chiny[83][44]

Francja[91]

Karrimycynaróżne miasta, Chiny[28][92]
OseltamiwirTongji, Chiny[93]
PrzeciwciałaChiny[94]
ImmunoglobulinyTongji, Chiny[95]

Hubei, Chiny[96]

MetyloprednizolonPekin, Chiny[97]

Tongji, Chiny[98]

Hubei, Chiny[99][100]

Chongqing, Chiny[101]

Dezaktywowane osocze przeciw wirusowi SARS-CoV-2Hubei, Chiny[102][103][104][105]
Osocze pobrane od rekonwalescentówZhejiang, Chiny[106]

Jiangsu, Chiny[107]

MeplazumabShaanxi, Chiny[108]
BewacyzumabShandong, Chiny[109]
EkulizumabUSA[110]
AdalimumabSzanghaj, Chiny[111]
vMIPHubei, China[112]
Komórki NKHenan, Chiny[113]
CytokinyShaanxi, Chiny[114]
MakrofagiChiny[115]
TymozynaChiny[94][116]
FingolimodFuzhou, Chiny[117]
PirfenidonHubei, Chiny[118][118]
Kwas poliinozyno-policytydylowy (pIC)Zhejiang, Chiny[119]
LeflunomidHubei, Chiny[120], USA[121]
Dihydroartemizynina/piperachinJiangxi, Chiny[122]
Tlenek azotuChiny[123][124]
Ciągłe pozaustrojowe natlenianie krwiChiny[125]
TalidomidChiny[126][127]
AmantadynaPolska[128]
DipirydamolChiny[129]
AcetylocysteinaHubei, Chiny[130]
Zasadowy cytrynian bizmutawyWuhan, Chiny[131]

Zobacz też

  • lista leków przeciwwirusowych

Przypisy

  1. ↑ a b Guangdi Li, Erik De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), „Nature Reviews. Drug Discovery”, 19 (3), 2020, s. 149–150, DOI: 10.1038/d41573-020-00016-0, PMID: 32127666 (ang.).
  2. ↑ Charlotte Harrison, Coronavirus puts drug repurposing on the fast track, „Nature Biotechnology”, 2020, DOI: 10.1038/d41587-020-00003-1 (ang.).
  3. ↑ Repurposed drugs may help scientists fight the new coronavirus, Science News, 10 marca 2020 [dostęp 2020-03-15] (ang.).
  4. ↑ Więcławski Tomasz: Tomasz Więcławski Prof. Zajkowska: nie dysponujemy badaniami potwierdzającymi skuteczność amantadyny w leczeniu COVID-19. PAP, 02.09.2021. [dostęp 2021-09-25].
  5. ↑ ClinicalTrials.gov: Efficacy of Amantadine Treatment in COVID-19 Patients (TITAN). 2021-07-07. [dostęp 2021-09-25].
  6. ↑ Ministerstwo Zdrowia rezygnuje z badań nad amantadyną, Onet.pl, 11 lutego 2022 [dostęp 2022-02-18] (pol.).
  7. ↑ a b Bin Cao, Yeming Wang, Mild/Moderate 2019-nCoV Remdesivir RCT, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04252664 [dostęp 2020-03-14] (ang.).
  8. ↑ a b Bin Cao, Severe 2019-nCoV Remdesivir RCT, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04257656 [dostęp 2020-03-14] (ang.).
  9. ↑ John Herbert Beigel, Adaptive COVID-19 Treatment Trial, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04280705 [dostęp 2020-03-14] (ang.).
  10. ↑ a b c d A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment, Gilead Sciences, fdaaa.trialstracker.net, NCT04292730 [dostęp 2020-03-14].
  11. ↑ a b c A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19, Gilead Sciences, fdaaa.trialstracker.net, NCT04292899 [dostęp 2020-03-14].
  12. ↑ A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. EudraCT Number: 2020-000842-32, www.clinicaltrialsregister.eu, dostęp 2020-15-03.
  13. ↑ A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 EudraCT Number: 2020-000841-15, www.clinicaltrialsregister.eu, dostęp 2020-15-03.
  14. ↑ A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029765 [dostęp 2020-03-15].
  15. ↑ Cancelled by the investigator Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030442 [dostęp 2020-03-15].
  16. ↑ Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report, London, UK: Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report, 9 stycznia 2021 [dostęp 2021-01-10].
  17. ↑ Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report, Londyn, UK: Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report, 9 stycznia 2021 [dostęp 2021-01-10].
  18. ↑ Roche’s Actemra, Regeneron’s Kevzara win U.K.'s favor in COVID-19 after study shows 24% drop in death risk, Framingham, Massachusetts, USA: Questex LLC, 8 stycznia 2021 [dostęp 2021-01-10].
  19. ↑ Qing Ning, Meifang Han, A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04255017 [dostęp 2020-03-14] (ang.).
  20. ↑ Zhang Dingyu, A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029308 [dostęp 2020-03-14].
  21. ↑ a b A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029609 [dostęp 2020-03-15].
  22. ↑ a b c d e Hongyi Chen, Zhicheng Zhang, Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus Infection, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04291729 [dostęp 2020-03-14] (ang.).
  23. ↑ Xie Liangdong, Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030218 [dostęp 2020-03-14].
  24. ↑ a b c 2019-nCoV Community Effort – Targeting 2019-nCoV Portal, ghddi-ailab.github.io, ChiCTR2000029387 [dostęp 2020-03-14] [zarchiwizowane z adresu 2020-03-06].
  25. ↑ a b c Peng Hu, Retracted due to lack of patient A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm, www.chictr.org.cn, ChiCTR2000029759 [dostęp 2020-03-14].
  26. ↑ Jianping Zhao, A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029539 [dostęp 2020-03-14].
  27. ↑ Zhijian Luo, Wei Xiao, Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19), apps.who.int, ChiCTR2000030187 [dostęp 2020-03-14].
  28. ↑ a b c d Huiguo Ding, Ying Han, The Clinical Study of Carrimycin on Treatment Patients With COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04286503 [dostęp 2020-03-14] (ang.).
  29. ↑ 新型コロナに対する臨床試験を全調査、ゾフルーザやアビガンの成分活用：日経バイオテクONLINE, bio.nikkeibp.co.jp, ChiCTR2000029468, ChiCTR2000029387, ChiCTR2000029386 [dostęp 2020-03-14].
  30. ↑ a b c Ting Li, Hua Jiang, A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19), apps.who.int, ChiCTR2000029468 [dostęp 2020-03-14].
  31. ↑ a b c Jianzhong Shentu, Qiu Yunqing, Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients, www.chictr.org.cn, ChiCTR2000029548 [dostęp 2020-03-14].
  32. ↑ a b Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study, www.chictr.org.cn, ChiCTR2000029741 [dostęp 2020-03-15].
  33. ↑ a b c A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection, www.chictr.org.cn, ChiCTR2000029573 [dostęp 2020-03-14].
  34. ↑ a b A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy, www.chictr.org.cn, ChiCTR2000029544 [dostęp 2020-03-14].
  35. ↑ Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir, www.chictr.org.cn, ChiCTR2000030113 [dostęp 2020-03-14].
  36. ↑ A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029996 [dostęp 2020-03-14].
  37. ↑ A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030254 [dostęp 2020-03-14].
  38. ↑ Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273763 [dostęp 2020-03-14] (ang.).
  39. ↑ A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04254874 [dostęp 2020-03-14] (ang.).
  40. ↑ Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029621 [dostęp 2020-03-14].
  41. ↑ Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04260594 [dostęp 2020-03-14] (ang.).
  42. ↑ a b Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04260594 [dostęp 2020-03-15] (ang.).
  43. ↑ Study for Arbidol Hydrochloride in the Prophylaxis of Novel Coronavirus Infection in High-risk Population with History of Exposed to COVID-19 pneumonia, www.chictr.org.cn, ChiCTR2000029592 [dostęp 2020-03-14].
  44. ↑ a b A prospective, randomized, open-label, parallel controlled clinical study to evaluate the preventive effect of hydroxychloroquine on medical personnel after exposure to novel coronavirus (COVID-19), www.chictr.org.cn, ChiCTR2000029803 [dostęp 2020-03-15].
  45. ↑ Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04288102 [dostęp 2020-03-14] (ang.).
  46. ↑ Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04293692 (ang.).
  47. ↑ Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273646 [dostęp 2020-03-14] (ang.).
  48. ↑ Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled tria, www.chictr.org.cn, ChiCTR2000029569 [dostęp 2020-03-14].
  49. ↑ Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial, www.chictr.org.cn, ChiCTR2000029572 [dostęp 2020-03-14].
  50. ↑ Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04269525 [dostęp 2020-03-14] (ang.).
  51. ↑ Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030224 [dostęp 2020-03-14].
  52. ↑ Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients, www.chictr.org.cn, ChiCTR2000030300 [dostęp 2020-03-14].
  53. ↑ Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04252118 [dostęp 2020-03-14] (ang.).
  54. ↑ Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029606 [dostęp 2020-03-14].
  55. ↑ A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04276987 [dostęp 2020-03-14] (ang.).
  56. ↑ Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030138 [dostęp 2020-03-14].
  57. ↑ Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04302519 [dostęp 2020-03-14] (ang.).
  58. ↑ Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029812 [dostęp 2020-03-14].
  59. ↑ Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029816 [dostęp 2020-03-14].
  60. ↑ Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029817 [dostęp 2020-03-14].
  61. ↑ Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029818 [dostęp 2020-03-14].
  62. ↑ Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029990 [dostęp 2020-03-14].
  63. ↑ Umbilical cord Wharton’s Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030088 [dostęp 2020-03-14].
  64. ↑ Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030116 [dostęp 2020-03-14].
  65. ↑ Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), fdaaa.trialstracker.net, NCT04299152 [dostęp 2020-03-14].
  66. ↑ Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04252274 [dostęp 2020-03-14] (ang.).
  67. ↑ A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029541 [dostęp 2020-03-14].
  68. ↑ A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029853 [dostęp 2020-03-14].
  69. ↑ A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030424 [dostęp 2020-03-14].
  70. ↑ A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030041 [dostęp 2020-03-14].
  71. ↑ The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial, www.chictr.org.cn, ChiCTR2000030001 [dostęp 2020-03-14].
  72. ↑ Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04293887 [dostęp 2020-03-15] (ang.).
  73. ↑ A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs., www.chictr.org.cn, ChiCTR2000030013 [dostęp 2020-03-15].
  74. ↑ Multicenter randomized controlled trial for novel recombinant high-efficiency compound interferon in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029638 [dostęp 2020-03-15].
  75. ↑ A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection in eliminating novel coronavirus in patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029496 [dostęp 2020-03-15].
  76. ↑ Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030262 [dostęp 2020-03-15].
  77. ↑ Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04261517 [dostęp 2020-03-15] (ang.).
  78. ↑ Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029542 [dostęp 2020-03-15].
  79. ↑ A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030031 [dostęp 2020-03-15].
  80. ↑ Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029559 [dostęp 2020-03-15].
  81. ↑ Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients（randomized open-label control clinical trial）, www.chictr.org.cn, ChiCTR2000029740 [dostęp 2020-03-15].
  82. ↑ Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029988 [dostęp 2020-03-15].
  83. ↑ a b A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19), www.chictr.org.cn, ChiCTR2000030054 [dostęp 2020-03-15].
  84. ↑ A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029762 [dostęp 2020-03-15].
  85. ↑ Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029761 [dostęp 2020-03-15].
  86. ↑ a b Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial, www.chictr.org.cn, ChiCTR2000029899 [dostęp 2020-03-15].
  87. ↑ a b Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial, www.chictr.org.cn, ChiCTR2000029898 [dostęp 2020-03-15].
  88. ↑ a b A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029992 [dostęp 2020-03-15].
  89. ↑ Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029975 [dostęp 2020-03-15].
  90. ↑ Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030417 [dostęp 2020-03-15].
  91. ↑ Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine. Clinical trials for eudract_number:2020-000890-25. www.clinicaltrialsregister.eu, dostęp 2020-03-15.
  92. ↑ The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial, www.chictr.org.cn [dostęp 2020-03-14].
  93. ↑ A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04261270 [dostęp 2020-03-14] (ang.).
  94. ↑ a b Immunoregulatory Therapy for 2019-nCoV, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04268537 [dostęp 2020-03-15] (ang.).
  95. ↑ The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04261426 [dostęp 2020-03-15] (ang.).
  96. ↑ Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04264858 [dostęp 2020-03-15] (ang.).
  97. ↑ Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04244591 [dostęp 2020-03-15] (ang.).
  98. ↑ The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04263402 [dostęp 2020-03-15] (ang.).
  99. ↑ Efficacy and Safety of Corticosteroids in COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273321 [dostęp 2020-03-15] (ang.).
  100. ↑ A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029656 [dostęp 2020-03-15].
  101. ↑ Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial, www.unboundmedicine.com, ChiCTR2000029386 [dostęp 2020-03-15] (ang.).
  102. ↑ A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19), www.chictr.org.cn, ChiCTR2000030010 [dostęp 2020-03-15].
  103. ↑ A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19), www.chictr.org.cn, ChiCTR2000030046 [dostęp 2020-03-15].
  104. ↑ Cancelled by investigator A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient, www.chictr.org.cn, ChiCTR2000030381 [dostęp 2020-03-15].
  105. ↑ Cancelled, due to modify the protocol A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment, www.chictr.org.cn, ChiCTR2000030312 [dostęp 2020-03-15].
  106. ↑ Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029850 [dostęp 2020-03-15].
  107. ↑ Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030039 [dostęp 2020-03-15].
  108. ↑ Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04275245 [dostęp 2020-03-15] (ang.).
  109. ↑ Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04275414 [dostęp 2020-03-15] (ang.).
  110. ↑ Eculizumab (Soliris) in Covid-19 Infected Patients, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04288713 [dostęp 2020-03-15] (ang.).
  111. ↑ A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030089 [dostęp 2020-03-15].
  112. ↑ Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial, www.chictr.org.cn, ChiCTR2000029636 [dostęp 2020-03-15].
  113. ↑ NK Cells Treatment for Novel Coronavirus Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04280224 [dostęp 2020-03-15] (ang.).
  114. ↑ Cancelled by the investigator Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030329 [dostęp 2020-03-15].
  115. ↑ Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029431 [dostęp 2020-03-15].
  116. ↑ Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029806 [dostęp 2020-03-15].
  117. ↑ Fingolimod in COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04280588 [dostęp 2020-03-15] (ang.).
  118. ↑ a b A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04282902 [dostęp 2020-03-15] (ang.).
  119. ↑ A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029776 [dostęp 2020-03-15].
  120. ↑ A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030058 [dostęp 2020-03-15].
  121. ↑ City of Hope Medical Center, Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy..., TrialBulletin.com [dostęp 2021-04-24] (ang.).
  122. ↑ Cancelled by the investigator Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030082 [dostęp 2020-03-15].
  123. ↑ Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04290858 [dostęp 2020-03-15] (ang.).
  124. ↑ Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04290871 [dostęp 2020-03-15] (ang.).
  125. ↑ Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000029804 [dostęp 2020-03-15].
  126. ↑ The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273581 [dostęp 2020-03-15] (ang.).
  127. ↑ The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT04273529 [dostęp 2020-03-15] (ang.).
  128. ↑ Członek Rady Medycznej: Amantadyna? Na razie nie zalecam, www.rp.pl, 30 marca 2021 [dostęp 2021-04-26].
  129. ↑ Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030055 [dostęp 2020-03-15].
  130. ↑ Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030328 [dostęp 2020-03-15].
  131. ↑ A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19), www.chictr.org.cn, ChiCTR2000030398 [dostęp 2020-03-15].
Pandemia COVID-19
Wg kontynentów:
Afryka
Azja, Australia i Oceania
Ameryka
Europa
Ameryka Płd.
Ameryka Płn.
Australia
i Oceania
Azja
Europa
Afryka
Szczepienia
Szczepionki
Prawo
Pozostałe

COVID-19 Outbreak World Map.svg

Star of life.svg Przeczytaj ostrzeżenie dotyczące informacji medycznych i pokrewnych zamieszczonych w Wikipedii.

Media użyte na tej stronie

COVID-19 Outbreak World Map.svg
Autor:

Various Commons editors. See file history for latest ones.

Older versions: Svenskbygderna (original author); Ratherous, AKS471883 (contributors); authors of File:BlankMap-World.svg (source file), Licencja: CC BY 4.0

Map of the COVID-19 outbreak. Total cumulative confirmed COVID-19 cases by country. See the file history farther down for the latest upload date. Be aware that since this is a rapidly evolving situation, new cases may not be immediately represented visually. Refer to the primary article COVID-19 pandemic or the World Health Organization's situation reports for most recent reported case information.

Legend information:

 
100,000,000+ Confirmed cases
 
10,000,000–99,999,999 Confirmed cases
 
1,000,000–9,999,999 Confirmed cases
 
100,000–999,999 Confirmed cases
 
10,000–99,999 Confirmed cases
 
1,000–9,999 Confirmed cases
 
100–999 Confirmed cases
 
1–99 Confirmed cases
 
No confirmed cases, no population, or no data available
Star of life.svg

The Star of Life, medical symbol used on some ambulances.

Star of Life was designed/created by a National Highway Traffic Safety Administration (US Gov) employee and is thus in the public domain.